Trials / Completed
CompletedNCT03809325
A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
Cross-sectional Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 225 (actual)
- Sponsor
- Janssen-Cilag International NV · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore the experience with paliperidone palmitate 3-month formulation (PP3M) treatment of participants and their corresponding physicians, nurses and carers, to understand the impact of less frequent injections from their perspective.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paliperidone Palmitate 3-Month Formulation (PP3M) | No intervention will be administered as a part of this study. Participants who have been treated with PP3M in clinical practice will be enrolled. |
Timeline
- Start date
- 2018-11-21
- Primary completion
- 2019-07-12
- Completion
- 2019-07-12
- First posted
- 2019-01-18
- Last updated
- 2025-04-27
Locations
41 sites across 7 countries: Belgium, France, Germany, Hungary, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT03809325. Inclusion in this directory is not an endorsement.